Left Ventricular Dysfunction

Subscribe to Selected New Research on Left Ventricular Dysfunction

2588 relevant articles (194 outcomes, 446 trials/studies) found for this Disease

Description: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.

Also Known As:

Ventricular Dysfunction, Left; Dysfunction, Left Ventricular; Dysfunctions, Left Ventricular; Left Ventricular Dysfunctions; Ventricular Dysfunctions, Left

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18525

Heart Diseases: 12357

Ventricular Dysfunction: 583

Left Ventricular Dysfunction: 2588

Takotsubo Cardiomyopathy: 81

Related Diseases

1.	Heart Failure
2.	Myocardial Infarction
3.	Coronary Artery Disease (Coronary Atherosclerosis)
4.	Infarction
5.	Hypertension (High Blood Pressure)

Experts

1.	Pitt, Bertram: 7 articles (09/2007 - 04/2003)
2.	McNitt, Scott: 5 articles (01/2008 - 06/2005)
3.	Moss, Arthur J: 5 articles (01/2008 - 06/2005)
4.	Zareba, Wojciech: 5 articles (01/2008 - 06/2005)
5.	Sharov, Victor G: 5 articles (08/2007 - 05/2002)
6.	Sabbah, Hani N: 5 articles (08/2007 - 05/2002)
7.	Goldstein, Sidney: 5 articles (08/2007 - 05/2002)
8.	Køber, Lars: 5 articles (12/2006 - 11/2003)
9.	Schultheiss, Heinz-Peter: 4 articles (06/2008 - 06/2002)
10.	Velazquez, Eric J: 4 articles (05/2008 - 11/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Left Ventricular Dysfunction:

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/01/1999 - "It is likely that not only patients with significant reduction of systolic function but also other signs of impaired left ventricular dysfunction will benefit from treatment with ACE inhibitors" 01/01/1996 - "It is likely that not only patients with significant reduction of systolic function but also other signs of impaired left ventricular dysfunction will benefit from treatment with ACE inhibitors" 01/01/1995 - "Angiotensin-converting enzyme inhibitors (ACE inhibitors) have been shown to be effective in improving symptoms and survival in patients with systolic left ventricular dysfunction" 08/01/1999 - "Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established" 07/01/1998 - "In particular, widespread awareness of the importance of the renin-angiotensin system (RAS) has occurred since experimental and clinical studies have detailed the efficacy of angiotensin-converting enzyme inhibitors in reducing morbidity and mortality in patients with left ventricular dysfunction" Order ALL the reference details at left...
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/01/2002 - "Angiotensin-converting enzyme (ACE) inhibition has been shown to be effective in reducing or preventing ischemic events in patients with and without left ventricular dysfunction, and in those at high risk for CAD" 07/01/1992 - "DATA SYNTHESIS: Angiotensin converting enzyme (ACE) inhibition therapy is effective in reducing mortality and morbidity in severe left ventricular dysfunction and CHF" 04/01/2008 - "I then show why the latter is an injudicious application of this statistical methodology, and illustrate this point with the example of an influential study in the biomedical literature that purported to demonstrate a lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction." 03/15/1999 - "OBJECTIVES: This analysis was performed to assess whether beta-adrenergic blocking agent use is associated with reduced mortality in the Studies of Left Ventricular Dysfunction (SOLVD) and to determine if this relationship is altered by angiotensin-converting enzyme (ACE) inhibitor use" 02/01/1995 - "Angiotensin-converting enzyme (ACE) inhibitor therapy has been associated with a substantial (> or = 20%) reduction in the risk of major ischemic events in two recent clinical trials with long-term follow-up: Studies of Left Ventricular Dysfunction (SOLVD) and the Survival and Ventricular Enlargement (SAVE) study" Order ALL the reference details at left...
3.	Dobutamine FDA LinkGeneric 11/01/1994 - "Improvement in wall motion during dobutamine echocardiography and normal or mildly decreased uptake on thallium-201 scanning are strong predictors of reversible left ventricular dysfunction" 12/01/2001 - "This study suggests that GI-Tl SPECT is superior to reinjection imaging and dobutamine echocardiography in predicting functional recovery after ischemic left ventricular dysfunction." 10/01/2007 - "CONCLUSIONS: Viability at dobutamine stress echocardiography independently predicts improved outcome following revascularization in non-diabetics as well as diabetic patients with ischaemic left ventricular dysfunction." 05/01/2005 - "BACKGROUND: Patients with severe left ventricular dysfunction and myocardial viability by dobutamine stress echocardiography (DSE) or F18-fluorodeoxyglucose-single-photon emission computed tomography (FDG-SPECT), experience improved survival after coronary revascularization" 06/01/2000 - "Nine patients had left ventricular dysfunction unchanged compared with the initial measurement without viability in the territory of the left anterior descending artery with low dose dobutamine (group 1); thirty-two patients had improved or normal left ventricular ejection fraction with myocardial viability (group 2)" Order ALL the reference details at left...
4.	Captopril (Capoten)FDA LinkGeneric 11/08/2004 - "METHODS: The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40%" 05/15/2008 - "Secondary analyses of large-scale clinical trials, such as the Captopril Prevention Project, the Heart Outcomes Prevention Evaluation, and the Studies of Left Ventricular Dysfunction trial, are revealing the potential benefits of these agents in diabetes prevention" 06/01/1993 - "Clinical trials show a beneficial effect of the ACE inhibitor captopril on the prevention of left ventricular dysfunction" 04/01/1993 - "Decisive for future therapeutic decision making are above all the results of the SAVE study which prefers captopril in patients with a yet asymptomatic left ventricular dysfunction" 09/01/1998 - "Therefore, captopril may delay the development of left ventricular dysfunction and thus the time for corrective surgery." Order ALL the reference details at left...
5.	carvedilol (Coreg)FDA LinkGeneric 02/15/2005 - "METHODS: The antiarrhythmic effect of carvedilol was examined in a placebo-controlled multicenter trial, the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study, which enrolled 1,959 patients with reduced left ventricular systolic function after AMI, 98% of whom were treated with an ACE inhibitor" 05/06/2004 - "Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)." 01/01/2003 - "All-cause mortality was reduced in patients who received carvedilol in addition to conventional therapy compared with those who received placebo plus conventional therapy in the Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) trial (enrolling 1959 patients with left ventricular dysfunction following acute MI)" 08/01/2002 - "For all these reasons, the CAPRICORN trial of carvedilol in post-MI left ventricular dysfunction was an important and eagerly awaited trial, which could show that carvedilol treatment post-MI on top of the so-called modern post-MI therapy reduces mortality" 10/15/2006 - "In conclusion, this review explores the experimental and clinical evidence supporting the preferential use of carvedilol in post-AMI patients with left ventricular dysfunction." Order ALL the reference details at left...
6.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 04/01/1982 - "clinical studies, both randomized and nonrandomized, that have subgrouped patients by the number of diseased coronary arteries and by the degree of left ventricular dysfunction all show that survival with single-vessel disease is excellent and not improved by operation" 09/01/1998 - "The study showed no significant difference between severity of vessel disease and occlusion, prevalence of the infarct related artery or left ventricular dysfunction in Group I and II. No agreement between ST-segment shifts and myocardial perfusion in the infarct zone was found" 04/01/1982 - "The results of most studies, however, suggest that bypass operation prolongs survival in symptomatic patients when left ventricular dysfunction coexists with double- and triple-vessel disease" 05/01/2004 - "RESULTS: By comparing the four different periods, an increase in older age, female sex, comorbidity, three-vessel disease, and severe left ventricular dysfunction was observed" 03/01/2004 - "However, the incidence of in-hospital adverse coronary events (reinfarction, coronary reocclusion, target vessel revascularization, and death) and severe left ventricular dysfunction was significantly higher in Group 1 (18.3 vs. 6.1%, p < 0.05 and 20.9 vs. 6.1%, p < 0.05, respectively)" Order ALL the reference details at left...
7.	eplerenone (Inspra)FDA Link 07/03/2003 - "Eplerenone in patients with left ventricular dysfunction." 07/03/2003 - "Eplerenone in patients with left ventricular dysfunction." 07/03/2003 - "Eplerenone in patients with left ventricular dysfunction." 05/01/2005 - "Eplerenone has similarly demonstrated significant benefits in experimental animals and in patients with left ventricular dysfunction after myocardial infarction" 10/01/2004 - "Recent data showed that in rats with left ventricular dysfunction after extensive myocardial infarction, eplerenone on top of ACE inhibition more effectively improved cardiac remodeling and molecular alterations than ACE inhibition alone." Order ALL the reference details at left...
8.	AldosteroneIBA 08/01/2004 - "Two major prospective trials, including one in which patients routinely received ACE inhibitor and beta blocker therapy, have shown that the use of an aldosterone blocker significantly reduces all-cause mortality, sudden cardiovascular death and hospitalisation in patients with acute or chronic left ventricular dysfunction or CHF" 10/14/2003 - "Aldosterone blockade in patients with systolic left ventricular dysfunction." 02/01/2008 - "Aldosterone blockade also may be beneficial in patients who have New York Heart Association class II heart failure, asymptomatic left ventricular dysfunction, and heart failure with preserved or normal left ventricular function" 03/31/2004 - "Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies." 02/01/2008 - "Aldosterone blockade has been shown to be effective in reducing mortality in patients who have severe heart failure because of systolic left ventricular dysfunction (SLVD) and those who have heart failure and SLVD post-myocardial infarction" Order ALL the reference details at left...
9.	Enalapril FDA LinkGeneric 05/15/1995 - "BACKGROUND: Studies of Left Ventricular Dysfunction (SOLVD) demonstrated that enalapril therapy significantly improved the clinical course of patients with left ventricular (LV) dysfunction" 04/15/2007 - "Data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized trial of enalapril versus placebo in patients with ejection fractions <or=35%, were analyzed" 11/01/2005 - "The rate of new-onset AF in patients with left ventricular dysfunction and mild to moderate HF enrolled in the SoLVD trials was significantly lower with enalapril than with placebo (5.4% vs 24% over 2.9 years, P < .0001)" 12/01/2003 - "Comparing survivors, enalapril generated annual cost savings greater than the average wholesale price of the drug at Studies of Left Ventricular Dysfunction mean dosage levels" 05/31/2003 - "BACKGROUND: In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic but not asymptomatic left ventricular systolic dysfunction during the trial" Order ALL the reference details at left...
10.	Brain Natriuretic Peptide (Natrecor)FDA Link 02/13/2007 - "Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial." 08/01/2003 - "This study sought to investigate whether the presence of right ventricular systolic dysfunction with pre-existing left ventricular systolic dysfunction is associated with higher plasma brain natriuretic peptide (BNP) levels, compared with patients with isolated left ventricular dysfunction" 01/01/2001 - "Studies have shown that brain natriuretic peptide (BNP) gene expression is rapidly induced in the infarcted heart and that plasma BNP levels reflect the degree of left ventricular dysfunction" 09/01/2008 - "B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients." 07/01/2008 - "Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide." Order ALL the reference details at left...

Therapies and Procedures

1.	Transplants (Transplant) 03/01/1980 - "Although 22 (79%) of the 28 grafts were patent, there was no significant improvement in resting left ventricular dysfunction as assessed by ejection fraction, left ventricular volume or left ventricular end-diastolic pressure" 10/01/2007 - "CONCLUSION: CABG in patients with left ventricular dysfunction was effective, with favorable early graft patency rates" 05/01/2008 - "RESULTS: Eight (24%) patients recovered completely, 10 (30%) died, 2 (6%) underwent heart transplants, and 13 (39%) were left with persistent left ventricular dysfunction" 01/01/1995 - "He was placed on the cardiac transplant list because of severe left ventricular dysfunction but was later removed because his symptoms and function improved" 05/01/1976 - "Thus, hemodynamic evidence of ischemic left ventricular dysfunction during stress may identify those patients who will show objective improvement in ventricular performance after bypass graft surgery." Order ALL the reference details at left...
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 11/01/1993 - "Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state." 08/01/1996 - "Our experience suggests that patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting may benefit from preoperative intraaortic balloon pump insertion, especially patients in functional class III or IV. This approach improved survival significantly, reduced hospital stay, and was more cost-effective." 09/01/2007 - "CONCLUSIONS: Coronary artery bypass grafting in patients with poor left ventricular dysfunction improved myocardial function" 12/01/2008 - "The aim of the present study was to examine the effect of severe left ventricular dysfunction on the activation of systemic inflammatory reaction during and after coronary artery bypass grafting (CABG)" 07/01/2005 - "METHODS: In this prospective randomized study, 22 patients with moderate left ventricular dysfunction (mean LVEF = 37.27%+/- 3.43%), who underwent elective coronary artery bypass surgery, were examined" Order ALL the reference details at left...
3.	Myocardial Revascularization 02/01/1998 - "At follow-up, mean ejection fraction was 37.5(8.4)%, and the overall functional status had improved: 12 patients (18%) had angina and eight (12%) were in NYHA class III and IV. Myocardial revascularization in patients with left ventricular dysfunction can be performed with acceptably low operative risk, good survival rate at 2 years, and functional status improvement" 01/01/1987 - "Improved functional results following myocardial revascularization in patients with left ventricular dysfunction." 06/01/1981 - "Improved long-term survival following myocardial revascularization in patients with severe left ventricular dysfunction." 07/01/2007 - "OBJECTIVE: To assess off-pump myocardial revascularization in patients with significant left ventricular dysfunction" 07/01/2007 - "Off-pump total myocardial revascularization in patients with left ventricular dysfunction." Order ALL the reference details at left...
4.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 11/03/2007 - "Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials." 12/01/2006 - "BACKGROUND: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2-5 years" 06/01/2005 - "Although many studies have shown that implantable cardioverter defibrillator (ICD) therapy improves the survival of patients with significant left ventricular dysfunction, the magnitude of effectiveness of ICD therapy in clinically defined subgroups remains uncertain" 06/01/2005 - "Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004." 12/01/2003 - "perspective would consider this a randomized controlled study of presence or absence of pacemaker therapy in patients with left ventricular dysfunction and indications for implantable defibrillator therapy" Order ALL the reference details at left...
5.	Angioplasty (Angioplasties) 08/01/1994 - "This study demonstrates that segmental left ventricular dysfunction is involved in determining sympathovagal imbalance in patients with one-vessel coronary artery disease; the reversal of left ventricular dysfunction by successful coronary angioplasty improves the heart period power spectrum" 11/01/2004 - "Emergency angioplasty and signs of left ventricular dysfunction were the main predictors of in-hospital mortality." 12/01/2003 - "Immediate and late results of coronary angioplasty in patients with severe left ventricular dysfunction." 01/01/2000 - "A left ventricular dysfunction (ejection fraction < 0.40) was present in 34% of patients; bypass surgery and coronary angioplasty were performed in 49.6% and in 27% of patients respectively" 09/01/1998 - "Reversible postischemic left ventricular dysfunction: treatment by coronary angioplasty]" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Left Ventricular Dysfunction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 194 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>